ࡱ>  l \pThe Free Software Foundation B=PF0*8X@"1 Helvetica1Courier1 Courier New1 Courier New1 Helvetica$#,##0_);($#,##0)$#,##0_);[Red]($#,##0)$#,##0.00_);($#,##0.00)$#,##0.00_);[Red]($#,##0.00)-**_($* #,##0_);_($* (#,##0);_($* "-"_);_(@_)*)'_(* #,##0_);_(* (#,##0);_(* "-"_);_(@_)5,2_($* #,##0.00_);_($* (#,##0.00);_($* "-"??_);_(@_)2+/_(* #,##0.00_);_(* (#,##0.00);_(* "-"??_);_(@_)2$#,##0.00;[Red]$#,##0.003$#,##0.00;[Red]($#,##0.00)4$#,##0;[Red]($#,##00)50.00%;[Red](0.00%)6 0%;[Red](0%)7#,##0.00;[Red](#,##0.00)8#,##0;[Red](#,##0)                + ) , *   Ј ~~ ؈ ~~#؈ ~~ ؈ ~~8#܈ ~~7#܈ ~~<#܈ ~~4#܈ ~~3#܈ ~~83ffff̙̙3f3fff3f3f33333f33 ARGOS THERAPEUTICS INC!To Be Held On July 28 2017%T$To Be Held On July 28 2017 (1).Beneficial Ownership5FSummary Compensation&SQUESTIONS AND ANSWERS ABOUT THE&bQUESTIONS AND ANSWERS ABOUT (1)wqBeneficial Ownership (1)xBeneficial Ownership (2)͊NO TITLE&DInformation about our DirectorsAudit Fees and Services&BWhy We Are Requesting Stockhold&Why We Are Requesting Stock (1)New Plan Benefits&}APPROVAL OF AMENDMENT TO RESTAT&2016 Compensation of NonEmploye NO TITLE (1)&2016 Compensation of NonEmp (1)&Executive Officers of Argos The&Participation in our 2016 PIPE &* Participation in our FollowOn  7Summary Compensation (1)>Summary Compensation (2) $ROutstanding Equity Awardsއ 1 Appendix C l  1  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??To Be Held On July 28 2017 To Be Held On July 28 2017 (1)Beneficial OwnershipSummary Compensation!QUESTIONS AND ANSWERS ABOUT THE!QUESTIONS AND ANSWERS ABOUT (1)Beneficial Ownership (1)Beneficial Ownership (2) NO TITLE!Information about our DirectorsAudit Fees and Services!Why We Are Requesting Stockhold!Why We Are Requesting Stock (1)New Plan Benefits!APPROVAL OF AMENDMENT TO RESTAT!2016 Compensation of NonEmploye NO TITLE (1)!2016 Compensation of NonEmp (1)!Executive Officers of Argos The!Participation in our 2016 PIPE ! Participation in our FollowOn Summary Compensation (1)Summary Compensation (2)Outstanding Equity Awards 1 Appendix CU } $} U} 2      ARGOS THERAPEUTICS INCDEF 14A 07/06/2017 ARGOS THERAPEUTICS, INC. xNo fee required.   ?0 (Fee computed on table below per Exchange ' Act Rules 14a-6(i)(1) and 0-11.   ~ 2*Title of each class of securities to whichtransaction applies:$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.Qyma8, 4=PF0*8X> @2   l  '!#  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INC To Be Held On July 28 2017 (1)Beneficial OwnershipSummary Compensation!QUESTIONS AND ANSWERS ABOUT THE!QUESTIONS AND ANSWERS ABOUT (1)Beneficial Ownership (1)Beneficial Ownership (2) NO TITLE!Information about our DirectorsAudit Fees and Services!Why We Are Requesting Stockhold!Why We Are Requesting Stock (1)New Plan Benefits!APPROVAL OF AMENDMENT TO RESTAT!2016 Compensation of NonEmploye NO TITLE (1)!2016 Compensation of NonEmp (1)!Executive Officers of Argos The!Participation in our 2016 PIPE ! Participation in our FollowOn Summary Compensation (1)Summary Compensation (2)Outstanding Equity Awards 1 Appendix CU } $ } $} 7 '     ARGOS THERAPEUTICS INCDEF 14A 07/06/2017#To Be Held On July 28, 2017~  .&The ratification of the appointment of  5 -PricewaterhouseCoopers LLP as our independent  - %registered public accounting firm for  * "the year ending December 31, 2017;    ~ 0 (The approval of an amendment to our 20143+Stock Incentive Plan to increase the number0(of shares of common stock authorized for/'issuance under the 2014 Stock Incentive4,Plan and to modify the ?evergreen? provision0(under the 2014 Stock Incentive Plan (the?Plan Amendment?).~ 4,The approval of an amendment to our Restated.&Certificate of Incorporation to effect2*a reverse stock split of our common stock,3+by a ratio of not less than 1-for-5 and not.&more than 1-for-20, such ratio and the1)implementation and timing of such reverse6.stock split to be determined in the discretion/'of our board of directors (the ?Reverse$Stock Split Amendment?); and~ 2*The transaction of any other business thatD lvj^x2q%>Haw7 !"#$%&  0 (may properly come before the 2017 annual!!+!#meeting or any adjournment thereof."#$$____________________________1%)Created by Morningstar Document Research.0&(http://documentresearch.morningstar.com/xmaU-=PF0*8X> @&&%%$$ l  <.  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTo Be Held On July 28 2017Beneficial OwnershipSummary Compensation!QUESTIONS AND ANSWERS ABOUT THE!QUESTIONS AND ANSWERS ABOUT (1)Beneficial Ownership (1)Beneficial Ownership (2) NO TITLE!Information about our DirectorsAudit Fees and Services!Why We Are Requesting Stockhold!Why We Are Requesting Stock (1)New Plan Benefits!APPROVAL OF AMENDMENT TO RESTAT!2016 Compensation of NonEmploye NO TITLE (1)!2016 Compensation of NonEmp (1)!Executive Officers of Argos The!Participation in our 2016 PIPE ! Participation in our FollowOn Summary Compensation (1)Summary Compensation (2)Outstanding Equity Awards 1 Appendix CU } $ } $} UN      ARGOS THERAPEUTICS INCDEF 14A 07/06/2017#To Be Held On July 28, 2017 ?IAVote over the Internet , by going to www.envisionreports.com/ARGS  5 -(have your proxy card in hand when you access    the website);  ?4 ,Vote by Telephone , by calling the toll-free  . &number 1-800-652-8683 (have your proxy  $ card in hand when you call); ?4,Vote by Mail , by returning the accompanying)!proxy card (signed and dated); or ?3+Vote in person at the 2017 annual meeting .$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0vj^v%Ju=PF0*8X> @ l  G;DE  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTo Be Held On July 28 2017 To Be Held On July 28 2017 (1)Summary Compensation!QUESTIONS AND ANSWERS ABOUT THE!QUESTIONS AND ANSWERS ABOUT (1)Beneficial Ownership (1)Beneficial Ownership (2) NO TITLE!Information about our DirectorsAudit Fees and Services!Why We Are Requesting Stockhold!Why We Are Requesting Stock (1)New Plan Benefits!APPROVAL OF AMENDMENT TO RESTAT!2016 Compensation of NonEmploye NO TITLE (1)!2016 Compensation of NonEmp (1)!Executive Officers of Argos The!Participation in our 2016 PIPE ! Participation in our FollowOn Summary Compensation (1)Summary Compensation (2)Outstanding Equity Awards 1 Appendix CU } 6}  G     ARGOS THERAPEUTICS INCDEF 14A 07/06/2017Beneficial Ownership.&QUESTIONS AND ANSWERS ABOUT THE ANNUAL~   MEETING AND VOTING0 (SECURITY OWNERSHIP OF CERTAIN BENEFICIAL~  OWNERS AND MANAGEMENT4 ,Section 16(a) Beneficial Ownership Reporting~ "  Compliance*"PROPOSAL 1 - ELECTION OF DIRECTORS~ &,$Directors and Nominees for Directors~ &'Information About our Directors~ &4,Nominees for Election as Class III Directors~ &&Directors Continuing in Office~ *4,PROPOSAL 2 - RATIFICATION OF THE APPOINTMENT~ 23+OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMAudit Fees and Services~ 2AUDIT COMMITTEE REPORT~ 63+PROPOSAL 3 ? APPROVAL OF THE PLAN AMENDMENT~ :2*Why We Are Requesting Stockholder Approval~ :of the Plan Amendment/'Description of the 2014 Stock Incentive~ >*"Plan, as amended by Plan Amendment'Federal Income Tax Consequences~ R2*PROPOSAL 4 ? APPROVAL OF THE REVERSE STOCK~ ZSPLIT AMENDMENTDl}qe%^H OY)> !"#$%&'()*+,-./0123456789:;<=>?. &Background and Reasons for the Reverse~ Z.!&Stock Split; Potential Consequences of"the Reverse Stock Split.#&Procedure for Implementing the Reverse~ #^$ Stock Split4%,Effect of the Reverse Stock Split on Holders~ %b#&of Outstanding Common Stock)'!Authorized Shares of Common Stock~ 'b0((Beneficial Holders of Common Stock (i.e.~ (b-)%stockholders who hold in street name)1*)Registered ?Book-Entry? Holders of Common~ *f4+,Stock (i.e. stockholders that are registered1,)on the transfer agent?s books and records+-#but do not hold stock certificates)&.Exchange of Stock Certificates~ .f/Fractional Shares~ /f051-Effect of the Reverse Stock Split on Employee~ 1j02(Plans, Options, Restricted Stock Awards,&3Warrants and Convertible Notes4Accounting Matters~ 4j556-Material U.S. Federal Income Tax Consequences~ 6j"7of the Reverse Stock Split8CORPORATE GOVERNANCE~ 8r9General~ 9r':Corporate Governance Guidelines~ :r";Board Leadership Structure~ ;r<Director Independence~ <v$=Board and Committee Meetings~ =v#>Director Nomination Process~ >~(? Communications from Stockholders~ ?Dlk+l*~Id0a3v@@ABCDEF@Oversight of Risk~ @AABC$D____________________________1E)Created by Morningstar Document Research.0F(http://documentresearch.morningstar.com/xx}=PF0*8X> @FFEEDD l  %%RzS  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTo Be Held On July 28 2017 To Be Held On July 28 2017 (1)Beneficial Ownership!QUESTIONS AND ANSWERS ABOUT THE!QUESTIONS AND ANSWERS ABOUT (1)Beneficial Ownership (1)Beneficial Ownership (2) NO TITLE!Information about our DirectorsAudit Fees and Services!Why We Are Requesting Stockhold!Why We Are Requesting Stock (1)New Plan Benefits!APPROVAL OF AMENDMENT TO RESTAT!2016 Compensation of NonEmploye NO TITLE (1)!2016 Compensation of NonEmp (1)!Executive Officers of Argos The!Participation in our 2016 PIPE ! Participation in our FollowOn Summary Compensation (1)Summary Compensation (2)Outstanding Equity Awards 1 Appendix CU } U5}   %     ARGOS THERAPEUTICS INCDEF 14A 07/06/2017Summary Compensation+#Code of Business Conduct and Ethics~ - %Compensation Committee Interlocks and~  Insider Participation Director Compensation~ 1 )Executive Officers of Argos Therapeutics,~  Inc.)!TRANSACTIONS WITH RELATED PERSONS~ 0(Participation in our 2016 PIPE Financing~ -%Participation in our Follow-On Public~ Offering0(Participation in our 2017 Note Financing~ "Indemnification Agreements~ 2*Policies and Procedures for Related Person~  TransactionsEXECUTIVE COMPENSATION~ "Summary Compensation Table~ -%Outstanding Equity Awards at December~ 31, 20164,Agreements with our Named Executive Officers~ 401(k) Retirement Plan~ STOCKHOLDER PROPOSALS~  Appendix A A-1 Appendix B B-1 to B-10 Appendix C C-1 to C-2Dl}qe(VF v4t@wH# !"#$ !$"____________________________1#)Created by Morningstar Document Research.0$(http://documentresearch.morningstar.com/ P=PF0*8X> @$$##"" l  &`yb  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTo Be Held On July 28 2017 To Be Held On July 28 2017 (1)Beneficial OwnershipSummary Compensation!QUESTIONS AND ANSWERS ABOUT (1)Beneficial Ownership (1)Beneficial Ownership (2) NO TITLE!Information about our DirectorsAudit Fees and Services!Why We Are Requesting Stockhold!Why We Are Requesting Stock (1)New Plan Benefits!APPROVAL OF AMENDMENT TO RESTAT!2016 Compensation of NonEmploye NO TITLE (1)!2016 Compensation of NonEmp (1)!Executive Officers of Argos The!Participation in our 2016 PIPE ! Participation in our FollowOn Summary Compensation (1)Summary Compensation (2)Outstanding Equity Awards 1 Appendix CU } U} 8 &     ARGOS THERAPEUTICS INCDEF 14A 07/06/2017A9QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING AND VOTING Q:0(Why did I receive these proxy materials?   A:7 /Our board of directors has made these materials / 'available to you in connection with the 3 +solicitation of proxies for use at our 2017 1 )annual meeting of stockholders to be held4,at the Hamner Conference Center at the North.&Carolina Biotechnology Center, 15 T.W.0(Alexander Drive, Research Triangle Park,0(North Carolina 27709 on Friday, July 28,2*2017 at 10:00 a.m., Eastern Daylight Time.4,As a holder of common stock, you are invited1)to attend the 2017 annual meeting and are2*requested to vote on the items of business/'described in this proxy statement. This,$proxy statement includes information4,that we are required to provide to you under0(SEC rules and that is designed to assist"you in voting your shares. Q.7/What is the purpose of the 2017 annual meeting? A.0(At the 2017 annual meeting, stockholders/'will consider and vote on the followingDldXL@^XRT=% !"#$%  matters:!"$#____________________________1$)Created by Morningstar Document Research.0%(http://documentresearch.morningstar.com/Ad=PF0*8X> @%%$$## l  &ko q  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTo Be Held On July 28 2017 To Be Held On July 28 2017 (1)Beneficial OwnershipSummary Compensation!QUESTIONS AND ANSWERS ABOUT THEBeneficial Ownership (1)Beneficial Ownership (2) NO TITLE!Information about our DirectorsAudit Fees and Services!Why We Are Requesting Stockhold!Why We Are Requesting Stock (1)New Plan Benefits!APPROVAL OF AMENDMENT TO RESTAT!2016 Compensation of NonEmploye NO TITLE (1)!2016 Compensation of NonEmp (1)!Executive Officers of Argos The!Participation in our 2016 PIPE ! Participation in our FollowOn Summary Compensation (1)Summary Compensation (2)Outstanding Equity Awards 1 Appendix CU } U} : &     ARGOS THERAPEUTICS INCDEF 14A 07/06/2017A9QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING AND VOTING Q.0(Who can vote at the 2017 annual meeting?   A.2 *To be entitled to vote, you must have been 8 0a stockholder of record at the close of business 5 -on June 9, 2017, the record date for our 2017 - %annual meeting. There were 41,353,570.&shares of our common stock outstanding7/and entitled to vote at the 2017 annual meetingas of the record date. Q.!How many votes do I have? A.3+Each share of our common stock that you own1)as of the record date will entitle you to1)one vote on each matter considered at the2017 annual meeting. Q.How do I vote? A.6.If you are the ?record holder? of your shares,/'meaning that your shares are registered3+in your name in the records of our transfer1)agent, Computershare Trust Company, N.A.,2*you may vote your shares at the meeting inDVldXL@ZS% } @%%$$## l  Xx  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTo Be Held On July 28 2017 To Be Held On July 28 2017 (1)Beneficial OwnershipSummary Compensation!QUESTIONS AND ANSWERS ABOUT THE!QUESTIONS AND ANSWERS ABOUT (1)Beneficial Ownership (2) NO TITLE!Information about our DirectorsAudit Fees and Services!Why We Are Requesting Stockhold!Why We Are Requesting Stock (1)New Plan Benefits!APPROVAL OF AMENDMENT TO RESTAT!2016 Compensation of NonEmploye NO TITLE (1)!2016 Compensation of NonEmp (1)!Executive Officers of Argos The!Participation in our 2016 PIPE ! Participation in our FollowOn Summary Compensation (1)Summary Compensation (2)Outstanding Equity Awards 1 Appendix CU } 1} $} $      ARGOS THERAPEUTICS INCDEF 14A 07/06/2017Beneficial Ownership ?&each of our current directors;  $ ____________________________1 )Created by Morningstar Document Research.0 (http://documentresearch.morningstar.com/ }qe" =PF0*8X> @ l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTo Be Held On July 28 2017 To Be Held On July 28 2017 (1)Beneficial OwnershipSummary Compensation!QUESTIONS AND ANSWERS ABOUT THE!QUESTIONS AND ANSWERS ABOUT (1)Beneficial Ownership (1) NO TITLE!Information about our DirectorsAudit Fees and Services!Why We Are Requesting Stockhold!Why We Are Requesting Stock (1)New Plan Benefits!APPROVAL OF AMENDMENT TO RESTAT!2016 Compensation of NonEmploye NO TITLE (1)!2016 Compensation of NonEmp (1)!Executive Officers of Argos The!Participation in our 2016 PIPE ! Participation in our FollowOn Summary Compensation (1)Summary Compensation (2)Outstanding Equity Awards 1 Appendix CU } 1} $ } } $ }  } $                                 ARGOS THERAPEUTICS INCDEF 14A 07/06/2017Beneficial Ownership,$Name and Address of Beneficial Owner Number ofPercentage of Shares   Shares  Beneficially Owned    Beneficially   Owned 5% Stockholders:        , $Pharmstandard International S.A. (1)  ~ `    zGC@ %ForArgos B.V. (2)~ &ffffff4@1)TVM V Life Science Ventures GmbH & Co. KG~ 6׊@~ /'Directors and Named Executive Officers:,$Sander van Deventer, M.D., Ph.D. (4)~ L(= ףp}4@ Hubert Birner, Ph.D. (5)~ = ףp=@Robert Carey (6)~ Q?!Irackly Mtibelishvily (7)~ 6? Igor Krol (8)~ B {Gz?Jeffrey D. Abbey (9)~ R5 ףp= @( Charles A. Nicolette, Ph.D. (10)~ 2Q?Lee Allen M.D. (11)~ Q?/'All executive officers and directors as~ Z(\5<@ % a group (9 persons) (12)$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/D l}qed;&c?.% nJ>=PF0*8X> @J      l  :  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTo Be Held On July 28 2017 To Be Held On July 28 2017 (1)Beneficial OwnershipSummary Compensation!QUESTIONS AND ANSWERS ABOUT THE!QUESTIONS AND ANSWERS ABOUT (1)Beneficial Ownership (1)Beneficial Ownership (2)!Information about our DirectorsAudit Fees and Services!Why We Are Requesting Stockhold!Why We Are Requesting Stock (1)New Plan Benefits!APPROVAL OF AMENDMENT TO RESTAT!2016 Compensation of NonEmploye NO TITLE (1)!2016 Compensation of NonEmp (1)!Executive Officers of Argos The!Participation in our 2016 PIPE ! Participation in our FollowOn Summary Compensation (1)Summary Compensation (2)Outstanding Equity Awards 1 Appendix CU } U} $ } 8 :     ARGOS THERAPEUTICS INCDEF 14A 07/06/2017NO TITLE~ 2*Consists of (i) 2,274,765 shares of common  6 .stock beneficially owned by TVM V as described  1 )in footnote (3) above, (ii) 12,680 shares  0 (of common stock owned directly and (iii)  . &31,500 shares of common stock issuable  5 -upon exercise of options that are exercisable7/as of April 15, 2017 or will become exercisable'within 60 days after such date.~ 4,Consists of (i) 8,206 shares of common stock7/and (ii) 20,500 shares of common stock issuable5-upon exercise of options that are exercisable7/as of April 15, 2017 or will become exercisable'within 60 days after such date.~ /'Consists of (i) 14,895 shares of common3+stock and (ii) 5,000 shares of common stock.&issuable upon exercise of options that4,are exercisable as of April 15, 2017 or will/'become exercisable within 60 days after such date.~ 4,Consists of (i) 3,874 shares of common stock7/and (ii) 13,166 shares of common stock issuableD l}q!6H @998877 l  %  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTo Be Held On July 28 2017 To Be Held On July 28 2017 (1)Beneficial OwnershipSummary Compensation!QUESTIONS AND ANSWERS ABOUT THE!QUESTIONS AND ANSWERS ABOUT (1)Beneficial Ownership (1)Beneficial Ownership (2) NO TITLEAudit Fees and Services!Why We Are Requesting Stockhold!Why We Are Requesting Stock (1)New Plan Benefits!APPROVAL OF AMENDMENT TO RESTAT!2016 Compensation of NonEmploye NO TITLE (1)!2016 Compensation of NonEmp (1)!Executive Officers of Argos The!Participation in our 2016 PIPE ! Participation in our FollowOn Summary Compensation (1)Summary Compensation (2)Outstanding Equity Awards 1 Appendix CU } *} $ } $} $ } 0.      ARGOS THERAPEUTICS INCDEF 14A 07/06/2017'Information about our Directors Name AgePosition  Jeffrey Abbey  ~   . &President, Chief Executive Officer and       Director# Hubert Birner, Ph.D. (1)(3)  ~   * "Chairman of the Board of Directors Robert Carey (1)(2)  ~    Director+ #Sander van Deventer M.D., Ph.D. (2)  ~    Director!Irackly Mtibelishvily (3)~ Director Igor Krol~ Director$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.~rfZ*&.=PF0*8X> @" l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTo Be Held On July 28 2017 To Be Held On July 28 2017 (1)Beneficial OwnershipSummary Compensation!QUESTIONS AND ANSWERS ABOUT THE!QUESTIONS AND ANSWERS ABOUT (1)Beneficial Ownership (1)Beneficial Ownership (2) NO TITLE!Information about our Directors!Why We Are Requesting Stockhold!Why We Are Requesting Stock (1)New Plan Benefits!APPROVAL OF AMENDMENT TO RESTAT!2016 Compensation of NonEmploye NO TITLE (1)!2016 Compensation of NonEmp (1)!Executive Officers of Argos The!Participation in our 2016 PIPE ! Participation in our FollowOn Summary Compensation (1)Summary Compensation (2)Outstanding Equity Awards 1 Appendix CU } '} $ } $} $ }  } $                     ARGOS THERAPEUTICS INCDEF 14A 07/06/2017Audit Fees and Services~ ~ ~ Audit Fees (1) ~   ~ j8  Audit-Related Fees (2)   ?    ?   Tax Fees (3)   ?   ~ ~1  All Other Fees (4)   ?    ? (  Total Fees for Services Provided ~   ~ i $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*`hznb"8==PF0*8X> @J      l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTo Be Held On July 28 2017 To Be Held On July 28 2017 (1)Beneficial OwnershipSummary Compensation!QUESTIONS AND ANSWERS ABOUT THE!QUESTIONS AND ANSWERS ABOUT (1)Beneficial Ownership (1)Beneficial Ownership (2) NO TITLE!Information about our DirectorsAudit Fees and Services!Why We Are Requesting Stock (1)New Plan Benefits!APPROVAL OF AMENDMENT TO RESTAT!2016 Compensation of NonEmploye NO TITLE (1)!2016 Compensation of NonEmp (1)!Executive Officers of Argos The!Participation in our 2016 PIPE ! Participation in our FollowOn Summary Compensation (1)Summary Compensation (2)Outstanding Equity Awards 1 Appendix CU } a} $ } y} $ } }  $ } U} $                        ARGOS THERAPEUTICS INCDEF 14A 07/06/2017H@Why We Are Requesting Stockholder Approval of the Plan Amendment Fiscal YearEquityBasic Weighted   Gross Burn   Awards  Average Number  Rate(1)   Granted   of Shares of        Common Stock        Outstanding~   ~     ~ Zy    ffffff@ %~ ~~ #.~ v    @  %~ z~ ~;~  $   ffffff@  %Three-Year Average~ *N~ 2   @  %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0]QE9M?DsK=PF0*8X> @j           l  C  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTo Be Held On July 28 2017 To Be Held On July 28 2017 (1)Beneficial OwnershipSummary Compensation!QUESTIONS AND ANSWERS ABOUT THE!QUESTIONS AND ANSWERS ABOUT (1)Beneficial Ownership (1)Beneficial Ownership (2) NO TITLE!Information about our DirectorsAudit Fees and Services!Why We Are Requesting StockholdNew Plan Benefits!APPROVAL OF AMENDMENT TO RESTAT!2016 Compensation of NonEmploye NO TITLE (1)!2016 Compensation of NonEmp (1)!Executive Officers of Argos The!Participation in our 2016 PIPE ! Participation in our FollowOn Summary Compensation (1)Summary Compensation (2)Outstanding Equity Awards 1 Appendix CU } 7} $ } y} $      ARGOS THERAPEUTICS INCDEF 14A 07/06/2017H@Why We Are Requesting Stockholder Approval of the Plan AmendmentJune 9,  ~ / 'Total shares of common stock underlying  ~ FFc  all outstanding options6 .Weighted-average exercise price of outstanding  p= ף@  options.&Weighted-average remaining contractualHzG@.&life of outstanding options (in years)0(Total shares available for future awards~ 6V$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0x]QE9`O=PF0*8X> @2   l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTo Be Held On July 28 2017 To Be Held On July 28 2017 (1)Beneficial OwnershipSummary Compensation!QUESTIONS AND ANSWERS ABOUT THE!QUESTIONS AND ANSWERS ABOUT (1)Beneficial Ownership (1)Beneficial Ownership (2) NO TITLE!Information about our DirectorsAudit Fees and Services!Why We Are Requesting Stockhold!Why We Are Requesting Stock (1)!APPROVAL OF AMENDMENT TO RESTAT!2016 Compensation of NonEmploye NO TITLE (1)!2016 Compensation of NonEmp (1)!Executive Officers of Argos The!Participation in our 2016 PIPE ! Participation in our FollowOn Summary Compensation (1)Summary Compensation (2)Outstanding Equity Awards 1 Appendix CU } 7} $ } y} $      ARGOS THERAPEUTICS INCDEF 14A 07/06/2017New Plan Benefits Name of Beneficial OwnerNumber of Shares of    Common Stock   Underlying Awards   Granted under the 2014   Stock Incentive Plan Named Executive Officers  ~ nl Jeffrey D. Abbey~ P>#Charles A. Nicolette, Ph.D.~ !!Lee F. Allen, M.D., Ph.D.~  4,All current executive officers as a group(1)~ V!q6.All directors (who are not executive officers)~   as a groupNominees for director~ +@Jeffrey D. Abbey~ P>Irackly Mtibelishvily~ 2*All other employees, including all current~ :0(officers who are not executive officers, as a group$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/>y0thzBEar\4=PF0*8X> @B     l  9  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTo Be Held On July 28 2017 To Be Held On July 28 2017 (1)Beneficial OwnershipSummary Compensation!QUESTIONS AND ANSWERS ABOUT THE!QUESTIONS AND ANSWERS ABOUT (1)Beneficial Ownership (1)Beneficial Ownership (2) NO TITLE!Information about our DirectorsAudit Fees and Services!Why We Are Requesting Stockhold!Why We Are Requesting Stock (1)New Plan Benefits!2016 Compensation of NonEmploye NO TITLE (1)!2016 Compensation of NonEmp (1)!Executive Officers of Argos The!Participation in our 2016 PIPE ! Participation in our FollowOn Summary Compensation (1)Summary Compensation (2)Outstanding Equity Awards 1 Appendix CU } $ } $} 6      ARGOS THERAPEUTICS INCDEF 14A 07/06/2017f^APPROVAL OF AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT ?1)the historical trading prices and trading  # volume of our common stock;  ?0 (the number of shares of our common stock    outstanding;  ?- %the then-prevailing trading price and  2 *trading volume of our common stock and the3+anticipated or actual impact of the Reverse4,Stock Split on the trading price and trading$volume for our common stock; ?.&the anticipated impact of a particular5-ratio on our ability to reduce administrative$and transactional costs; and ?.&prevailing general market and economic conditions.$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/:?3'Ay*OsD8,=PF0*8X> @ l  >  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTo Be Held On July 28 2017 To Be Held On July 28 2017 (1)Beneficial OwnershipSummary Compensation!QUESTIONS AND ANSWERS ABOUT THE!QUESTIONS AND ANSWERS ABOUT (1)Beneficial Ownership (1)Beneficial Ownership (2) NO TITLE!Information about our DirectorsAudit Fees and Services!Why We Are Requesting Stockhold!Why We Are Requesting Stock (1)New Plan Benefits!APPROVAL OF AMENDMENT TO RESTAT NO TITLE (1)!2016 Compensation of NonEmp (1)!Executive Officers of Argos The!Participation in our 2016 PIPE ! Participation in our FollowOn Summary Compensation (1)Summary Compensation (2)Outstanding Equity Awards 1 Appendix CU } <(} $ }  } U} $ }  }  $ } } $                            ARGOS THERAPEUTICS INCDEF 14A 07/06/20173+2016 Compensation of Non-Employee Directors NameFees Earned or Option Awards   Total    Paid in Cash ~   ~  ~  ~   Hubert Birner, Ph.D.  ~ ?~   ~ n   ~    Robert F. Carey  ~ 2~   ~ n   ~ 1   Igor Krol (2)  ~ 0~   ~    ~  " Irackly Mtibelishvily (3)~ >~ ~ Y  ~  x  Andrei Petrov (4)~ q~ ~ n  ~  N " Ralph Snyderman, M.D. (5)~ +~ ~   ~   & Brian J. Underdown, Ph.D. (6)~ ~ ~   ~   )! Sander van Deventer, M.D., Ph.D.~ p~ ~ n  ~    Philippe Van Holle (7)~ j~ ~ n  ~  & % Alexey Vinogradov, Ph.D. (8)~ N~ ~   ~  N $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8 rfZN2yUZ=PF0*8X> @Z        l  >  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTo Be Held On July 28 2017 To Be Held On July 28 2017 (1)Beneficial OwnershipSummary Compensation!QUESTIONS AND ANSWERS ABOUT THE!QUESTIONS AND ANSWERS ABOUT (1)Beneficial Ownership (1)Beneficial Ownership (2) NO TITLE!Information about our DirectorsAudit Fees and Services!Why We Are Requesting Stockhold!Why We Are Requesting Stock (1)New Plan Benefits!APPROVAL OF AMENDMENT TO RESTAT!2016 Compensation of NonEmploye!2016 Compensation of NonEmp (1)!Executive Officers of Argos The!Participation in our 2016 PIPE ! Participation in our FollowOn Summary Compensation (1)Summary Compensation (2)Outstanding Equity Awards 1 Appendix CU } } U5      ARGOS THERAPEUTICS INCDEF 14A 07/06/2017NO TITLE~ 1)Includes cash retainers of $2,808 in lieu 2 *of which Dr. Snyderman received 573 shares  of our common stock.~ 2 *Includes cash retainers of $11,872 in lieu 4 ,of which Dr. Underdown received 1,855 shares  of our common stock.~ 2*Includes cash retainers of $39,989 in lieu0(of which Dr. van Deventer received 7,352#shares of our common stock.~ 2*Includes cash retainers of $42,394 in lieu4,of which Mr. Van Holle received 7,621 sharesof our common stock.~ 2*Includes cash retainers of $15,571 in lieu.&of which Dr. Vinogradov received 2,480#shares of our common stock.$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/<}q.|8 U]=PF0*8X> @ l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTo Be Held On July 28 2017 To Be Held On July 28 2017 (1)Beneficial OwnershipSummary Compensation!QUESTIONS AND ANSWERS ABOUT THE!QUESTIONS AND ANSWERS ABOUT (1)Beneficial Ownership (1)Beneficial Ownership (2) NO TITLE!Information about our DirectorsAudit Fees and Services!Why We Are Requesting Stockhold!Why We Are Requesting Stock (1)New Plan Benefits!APPROVAL OF AMENDMENT TO RESTAT!2016 Compensation of NonEmploye NO TITLE (1)!Executive Officers of Argos The!Participation in our 2016 PIPE ! Participation in our FollowOn Summary Compensation (1)Summary Compensation (2)Outstanding Equity Awards 1 Appendix CU } <(} $ }  } $      ARGOS THERAPEUTICS INCDEF 14A 07/06/20173+2016 Compensation of Non-Employee Directors NameOption   Awards  Hubert Birner, Ph.D.  ~ W   Robert Carey  ~    Igor Krol  ~    Irackly Mtibelishvily  ~   Andrei Petrov~ W Ralph Snyderman, M.D.~  Brian Underdown, Ph.D.~ r)! Sander van Deventer, M.D., Ph.D.~ W Philippe Van Holle~ W! Alexey Vinogradov, Ph.D. ?$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6rfZN Xph=PF0*8X> @*  l  ;  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTo Be Held On July 28 2017 To Be Held On July 28 2017 (1)Beneficial OwnershipSummary Compensation!QUESTIONS AND ANSWERS ABOUT THE!QUESTIONS AND ANSWERS ABOUT (1)Beneficial Ownership (1)Beneficial Ownership (2) NO TITLE!Information about our DirectorsAudit Fees and Services!Why We Are Requesting Stockhold!Why We Are Requesting Stock (1)New Plan Benefits!APPROVAL OF AMENDMENT TO RESTAT!2016 Compensation of NonEmploye NO TITLE (1)!2016 Compensation of NonEmp (1)!Participation in our 2016 PIPE ! Participation in our FollowOn Summary Compensation (1)Summary Compensation (2)Outstanding Equity Awards 1 Appendix CU } !} $ } $} $ } $4      ARGOS THERAPEUTICS INCDEF 14A 07/06/20170(Executive Officers of Argos Therapeutics Name AgePosition Jeffrey D. Abbey (1)  ~   . &President, Chief Executive Officer and       Director# Charles A. Nicolette, Ph.D.  ~   3 +Chief Scientific Officer and Vice President      # of Research and Development Richard D. Katz, M.D.  ~   2 *Vice President and Chief Financial OfficerLori R. Harrelson~ !Vice President of Finance$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,?|ui]Qv~z=PF0*8X> @" l  )  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTo Be Held On July 28 2017 To Be Held On July 28 2017 (1)Beneficial OwnershipSummary Compensation!QUESTIONS AND ANSWERS ABOUT THE!QUESTIONS AND ANSWERS ABOUT (1)Beneficial Ownership (1)Beneficial Ownership (2) NO TITLE!Information about our DirectorsAudit Fees and Services!Why We Are Requesting Stockhold!Why We Are Requesting Stock (1)New Plan Benefits!APPROVAL OF AMENDMENT TO RESTAT!2016 Compensation of NonEmploye NO TITLE (1)!2016 Compensation of NonEmp (1)!Executive Officers of Argos The! Participation in our FollowOn Summary Compensation (1)Summary Compensation (2)Outstanding Equity Awards 1 Appendix CU } 1} $ } y} $ } y}  $                         ARGOS THERAPEUTICS INCDEF 14A 07/06/20170(Participation in our 2016 PIPE Financing NameShares Shares of  Purchase    Purchased  Common  Price       Stock        Underlying       Warrants        Purchased,$Pharmstandard International S.A. (1)~ ns~ V ~  ' .&Entities affiliated with ForArgos B.V.~ .~ fd ~  l ~ 1)TVM V Life Science Ventures GmbH & Co. KG~  ~  ~  ~ ~ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2ui]Qz!g P=PF0*8X> @             l  "6  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTo Be Held On July 28 2017 To Be Held On July 28 2017 (1)Beneficial OwnershipSummary Compensation!QUESTIONS AND ANSWERS ABOUT THE!QUESTIONS AND ANSWERS ABOUT (1)Beneficial Ownership (1)Beneficial Ownership (2) NO TITLE!Information about our DirectorsAudit Fees and Services!Why We Are Requesting Stockhold!Why We Are Requesting Stock (1)New Plan Benefits!APPROVAL OF AMENDMENT TO RESTAT!2016 Compensation of NonEmploye NO TITLE (1)!2016 Compensation of NonEmp (1)!Executive Officers of Argos The!Participation in our 2016 PIPE Summary Compensation (1)Summary Compensation (2)Outstanding Equity Awards 1 Appendix CU } 2} $ } y} $ } y}  $                       ARGOS THERAPEUTICS INCDEF 14A 07/06/2017LD_____________________ Participation in our Follow-On Public Offering NameShares Shares of  Purchase    Purchased  Common  Price       Stock        Underlying       Warrants        Purchased,$Pharmstandard International S.A. (1)~ C~ 2l ~  t 2*Entities affiliated with ForArgos B.V. (2)~ S^~ ʾF ~  v $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.YMA5^K4th\4=PF0*8X> @z            l  C>  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTo Be Held On July 28 2017 To Be Held On July 28 2017 (1)Beneficial OwnershipSummary Compensation!QUESTIONS AND ANSWERS ABOUT THE!QUESTIONS AND ANSWERS ABOUT (1)Beneficial Ownership (1)Beneficial Ownership (2) NO TITLE!Information about our DirectorsAudit Fees and Services!Why We Are Requesting Stockhold!Why We Are Requesting Stock (1)New Plan Benefits!APPROVAL OF AMENDMENT TO RESTAT!2016 Compensation of NonEmploye NO TITLE (1)!2016 Compensation of NonEmp (1)!Executive Officers of Argos The!Participation in our 2016 PIPE ! Participation in our FollowOn Summary Compensation (2)Outstanding Equity Awards 1 Appendix CU } 1} $ } 1      ARGOS THERAPEUTICS INCDEF 14A 07/06/2017Summary Compensation ?1)Jeffrey D. Abbey, our president and chief   executive officer;  $ ____________________________1 )Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/"}qe=PF0*8X> @ l  5Q  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTo Be Held On July 28 2017 To Be Held On July 28 2017 (1)Beneficial OwnershipSummary Compensation!QUESTIONS AND ANSWERS ABOUT THE!QUESTIONS AND ANSWERS ABOUT (1)Beneficial Ownership (1)Beneficial Ownership (2) NO TITLE!Information about our DirectorsAudit Fees and Services!Why We Are Requesting Stockhold!Why We Are Requesting Stock (1)New Plan Benefits!APPROVAL OF AMENDMENT TO RESTAT!2016 Compensation of NonEmploye NO TITLE (1)!2016 Compensation of NonEmp (1)!Executive Officers of Argos The!Participation in our 2016 PIPE ! Participation in our FollowOn Summary Compensation (1)Outstanding Equity Awards 1 Appendix CU } 2} $ }  } $ }  }  $ }  } $ } y} $ }  } $ } y} $      ARGOS THERAPEUTICS INCDEF 14A 07/06/2017Summary Compensation#Name and Principal Position YearSalary   Bonus Option All Other Total ($)      ~   ($) (1)  Awards   Compensation               ($) (2)  ($) (3) Jeffrey D. Abbey (4)  ~    ~ Bw   ~ R   ~ >   ~    ~ Vq - %President and Chief Executive Officer  ~ ~   ~ Bw   ~ \    ~ +   ~ 6   ~ WT " Charles A Nicolette, Ph.D.  ~    ~ "   ~ Np   ~ v,   ~ #   ~ jH 2*Vice President of Research and Development~ ~~ "  ~  .  ~ A~  ~ 6$and Chief Scientific Officer%Lee F. Allen, M.D., Ph.D. (5)~ ~   ~    ~ B >~ G~ rChief Medical Officer ?    ?   ? ? ?$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2 }qeMq=PF0*8X> @z       l  0vu  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTo Be Held On July 28 2017 To Be Held On July 28 2017 (1)Beneficial OwnershipSummary Compensation!QUESTIONS AND ANSWERS ABOUT THE!QUESTIONS AND ANSWERS ABOUT (1)Beneficial Ownership (1)Beneficial Ownership (2) NO TITLE!Information about our DirectorsAudit Fees and Services!Why We Are Requesting Stockhold!Why We Are Requesting Stock (1)New Plan Benefits!APPROVAL OF AMENDMENT TO RESTAT!2016 Compensation of NonEmploye NO TITLE (1)!2016 Compensation of NonEmp (1)!Executive Officers of Argos The!Participation in our 2016 PIPE ! Participation in our FollowOn Summary Compensation (1)Summary Compensation (2) 1 Appendix CU } !} $ }  } U} $ }  } U} $ } } U} $ } y } $ }  }  } $ }  }  0     ARGOS THERAPEUTICS INCDEF 14A 07/06/2017!Outstanding Equity Awards NameNumber of SecuritiesNumber of Securities  Option Option Number ofMarket    Underlying   Underlying  Exercise   Expiration   Shares or  Value of    Unexercised   Unexercised   Price ($)  Date  Units of   Shares or    Options (#)   Options (#)           Stock That  Units of    Exercisable   Unexercisable          Have Not   Stock That                   Vested  Have Not     VestedJeffrey D. Abbey~ ~~ ~    @~   7/2/18~ *Y~ ~    @~   12/5/18~ ~ ~    @~   12/10/20~ r~ ~    @~   4/10/22~ ~ ~    @~   12/11/22~ *~ ~ f~    HzG@  11/1/23~ ~ ~ z~    HzG@  11/11/23~ N'~ ~ 6i~    \(\@  7/27/24~ ~ X~    \(\@  7/27/24~ "~ ~ ~    333333@  6/16/25~ ~ BB~    p= ף@  6/12/26~ ~   ~    ~ ~ "G~ ~ \~ #Charles A. Nicolette, Ph.D.~ ~ ~    @~   7/2/18~ \~ ~    @~   12/5/18~ n~ ~    @~   12/10/20~ ~ ~    @~   4/10/22~ Fd~ ~    @~   12/11/22D*lxl`}|;v5s2\ !"#$%&'()*+,-./   ~ ޚ~   ~ B~    HzG@    11/1/23         !!!~ ! W~ !!!~ !e~ !! ! ! HzG@! ! !!11/11/23!!!!!!!!!"""~ "~ """~ "Vo~ "" " " \(\@" " ""7/27/24"""""""""###~ ####~ #~ ## # # \(\@# # ##7/27/24#########$$$~ $v~ $$$~ $n~ $$ $ $ 333333@$ $ $$6/16/25$$$$$$$$$%%%~ %%%%~ %b ~ %% % % p= ף@% % %%6/12/26%%%%%%%%%&&&~ &&&&~ &&& & ~ & & & &~ &&&&~ &"G~ &&&~ &\~ &!'Lee F. Allen, M.D., Ph.D.''~ ''''~ 'O~ '' ' ' Q@' ' ''1/19/26'''''''''(((~ ((((~ (~ (( ( ( q= ף%@( ( ((4/14/26((((((((()))~ ))))~ )~ )) ) ) 333333@) ) ))7/10/26)))))))))********** * * * * ***********+,$-____________________________1.)Created by Morningstar Document Research.0/(http://documentresearch.morningstar.com/$,}<}Ak?3'=PF0*8X> @ //..--                      l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??ARGOS THERAPEUTICS INCTo Be Held On July 28 2017 To Be Held On July 28 2017 (1)Beneficial OwnershipSummary Compensation!QUESTIONS AND ANSWERS ABOUT THE!QUESTIONS AND ANSWERS ABOUT (1)Beneficial Ownership (1)Beneficial Ownership (2) NO TITLE!Information about our DirectorsAudit Fees and Services!Why We Are Requesting Stockhold!Why We Are Requesting Stock (1)New Plan Benefits!APPROVAL OF AMENDMENT TO RESTAT!2016 Compensation of NonEmploye NO TITLE (1)!2016 Compensation of NonEmp (1)!Executive Officers of Argos The!Participation in our 2016 PIPE ! Participation in our FollowOn Summary Compensation (1)Summary Compensation (2)Outstanding Equity AwardsU } $ } } $      ARGOS THERAPEUTICS INCDEF 14A 07/06/2017 1 Appendix C ARGOS THERAPEUTICS, INC.      By:    Name:   Title:  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(Tym= {oG=PF0*8X> @2   Root Entry FBook  S  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~